RxDoctor Payments Data

Kwok Li, MD

Ophthalmology · Shenandoah, TXNPI 1487641353

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 57 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$283
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$241
  • Rxsight Inc$168
  • Bausch & Lomb Americas Inc.$160
  • Johnson & Johnson Surgical Vision, Inc.$129
  • Vertex$109
  • plus $587 from 13 others

What the payments were for

  • Food & beverage$1,66899%
  • Gifts$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$334,298
Medicare patients
561
Services billed
3,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast17$13,600
RestasisCyclosporine13$12,809
Prednisolone Acetate263$12,058
SimbrinzaBrinzolamide/Brimonidine Tart33$10,292
VyzultaLatanoprostene Bunod21$8,988
LumiganBimatoprost16$8,009
MoxifloxacinMoxifloxacin Hcl246$4,931
Ketorolac Tromethamine287$4,736
Latanoprost199$2,949
Brimonidine Tartrate34$2,802
Travoprost23$2,640
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$1,109
ValacyclovirValacyclovir Hcl15$931
Doxycycline Hyclate25$493
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$160$22,58838 claims
AbbVieRestasis, Lumigan$95$20,81729 claims
AlconSimbrinza$283$10,29233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →